Halozyme Therapeutics, Inc.

NASDAQ:HALO

54.8 (USD) • At close January 17, 2025
Bedrijfsnaam Halozyme Therapeutics, Inc.
Symbool HALO
Munteenheid USD
Prijs 54.8
Beurswaarde 6,972,039,600
Dividendpercentage 0%
52-weken bereik 33.15 - 65.53
Industrie Biotechnology
Sector Healthcare
CEO Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Website https://www.halozyme.com

An error occurred while fetching data.

Over Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies

Vergelijkbare Aandelen

Acadia Healthcare Company, Inc. logo

Acadia Healthcare Company, Inc.

ACHC

43.78 USD

Nutex Health, Inc. logo

Nutex Health, Inc.

NUTX

37.81 USD

Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc.

SRPT

118 USD

R1 RCM Inc. logo

R1 RCM Inc.

RCM

14.31 USD

ShockWave Medical, Inc. logo

ShockWave Medical, Inc.

SWAV

334.75 USD

Sotera Health Company logo

Sotera Health Company

SHC

12.98 USD

Exelixis, Inc. logo

Exelixis, Inc.

EXEL

36.2 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)